BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30687337)

  • 1. Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites.
    Wefers C; Duiveman-de Boer T; Yigit R; Zusterzeel PLM; van Altena AM; Massuger LFAG; De Vries IJM
    Front Immunol; 2018; 9():3156. PubMed ID: 30687337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
    Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
    J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
    Liu M; Xie J; Zhao S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma.
    Miceska S; Skof E; Bucek S; Kuhar CG; Gasljevic G; Smrkolj S; Prevodnik VK
    Radiol Oncol; 2023 Dec; 57(4):493-506. PubMed ID: 38038414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
    Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity.
    Peng P; Yan Y; Keng S
    Oncol Rep; 2011 Mar; 25(3):749-62. PubMed ID: 21181093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
    Clarke B; Tinker AV; Lee CH; Subramanian S; van de Rijn M; Turbin D; Kalloger S; Han G; Ceballos K; Cadungog MG; Huntsman DG; Coukos G; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):393-402. PubMed ID: 19060844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
    Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
    Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
    Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
    Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.
    McDonnell AM; Cook A; Robinson BWS; Lake RA; Nowak AK
    BMC Cancer; 2017 Jun; 17(1):417. PubMed ID: 28619093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
    da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase.
    Goyne HE; Stone PJ; Burnett AF; Cannon MJ
    J Immunother; 2014 Apr; 37(3):163-9. PubMed ID: 24598451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.